Reirradiation: Standards, challenges, and patient‐focused strategies across tumor types

A Arnaud Beddok (Department of Radiation Oncology Institut Godinot Reims France) J Jonas Willmann (Department of Radiation Oncology University Hospital Zurich University of Zurich Zurich Switzerland) A Anna Embring (Department of Oncology Karolinska University Hospital Stockholm Sweden) A Ane L. Appelt (Leeds Institute of Medical Research University of Leeds Leeds UK) P Panagiotis Balermpas (Department of Radiation Oncology University Hospital Zurich University of Zurich Zurich Switzerland) K Kevin Chua (Division of Radiation Oncology National Cancer Centre Singapore Singapore Singapore) J J. Isabelle Choi (Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York USA) B Bernice Simone Elger (Institute for Biomedical Ethics, University of Basel Basel Switzerland) D Dorota Gabrys (Department of Radiation Oncology Maria Sklodowska‐Curie National Research Institute of Oncology‐Gliwice Branch Glliwice Poland) P Peter Hoskin (Mount Vernon Cancer Center and University of Manchester Manchester UK) M Maximilian Niyazi (Department of Radiation Oncology University Hospital Tubingen Tubingen Germany) D David Pasquier (Academic Department of Radiation Oncology Oscar Lambret Center Lille France) K Kelly Paradis (Department of Radiation Oncology Michigan Medicine Ann Arbor Michigan USA) O Orit Kaidar‐Person (Oncology Institute Sheba Medical Center Ramat Gan Israel) C Corien Plaisier (Reintegration Coach Breda Netherlands) N Nicole C. Schmitt (Department of Otolaryngology‐Head and Neck Surgery Emory University School of Medicine Atlanta Georgia USA) C Conor E. Steuer (Department of Hematology and Medical Oncology Emory University Atlanta Georgia USA) J Juliette Thariat (Department of Radiation Oncology Baclesse Cancer Center Caen France) S Sue S. Yom (Department of Radiation Oncology University of California‐San Francisco San Francisco California USA) P Philip Poortmans (Department of Radiation Oncology Iridium Netwerk Wilrijk‐Antwerp Belgium) E Eliana Vasquez Osorio (Division of Cancer Sciences University of Manchester Manchester UK) N Nicolaus Andratschke (Department of Radiation Oncology University Hospital Zurich University of Zurich Zurich Switzerland)

Abstract

Abstract Reirradiation (reRT), defined as administering a course of radiation therapy to a specific area previously irradiated, is an evolving treatment strategy for locoregionally recurrent cancer that offers significant potential and poses inherent challenges. Advances in such techniques as intensity‐modulated and stereotactic body radiation therapy have improved precision, making reRT a viable option for complex scenarios previously deemed high‐risk. Nevertheless, reRT remains associated with substantial risks—including life‐threatening side effects, functional impairments, and psychosocial effects—which must be carefully balanced against the patient's overall health and the likelihood of achieving cancer control or palliation. Patient selection is essential to optimize outcomes while mitigating risks. Decisions should account for tumor characteristics at the time of primary diagnosis and recurrence, elapsed time since prior treatment, the possibility of delivering meaningful doses to the tumor, and the cumulative irradiation tolerance of normal tissues. Advanced imaging modalities, such as functional magnetic resonance imaging and fluorine‐18–labeled fluorodeoxyglucose–positron emission tomography, are important for distinguishing recurrences from treatment‐induced changes, refining treatment targets, and minimizing exposure to healthy tissue. Combined treatment with systemic regimens—targeted therapies and immunotherapy in particular—offers promising opportunities but requires coordination to manage side effects. Standardized guidelines, such as those from the European Society of Therapeutic Radiology and Oncology‐European Society for Research and Treatment of Cancer, are essential for improving the consistency of reporting, guiding clinical decision making, and fostering patient‐centered care. Multidisciplinary collaboration and ongoing research, particularly through clinical trials, are central to fully exploiting reRT strategies. In addition, the development of innovative techniques, such as proton therapy, would likely enable safer treatments. These efforts aim to improve the therapeutic balance of reRT, enhancing outcomes and quality of life.

Article Details

Volume / Issue Vol. 75, Issue 6
Published December 01, 2025
Pages 630-666
ISSN 0007-9235
Publisher Wiley

Journal Info

CA: A Cancer Journal for Clinicians

Wiley

ISSN: 0007-9235 Open Access Q1 Medicine

Authors (22)

A

Arnaud Beddok

Department of Radiation Oncology Institut Godinot Reims France

J

Jonas Willmann

Department of Radiation Oncology University Hospital Zurich University of Zurich Zurich Switzerland

A

Anna Embring

Department of Oncology Karolinska University Hospital Stockholm Sweden

A

Ane L. Appelt

Leeds Institute of Medical Research University of Leeds Leeds UK

P

Panagiotis Balermpas

Department of Radiation Oncology University Hospital Zurich University of Zurich Zurich Switzerland

K

Kevin Chua

Division of Radiation Oncology National Cancer Centre Singapore Singapore Singapore

J

J. Isabelle Choi

Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York USA

B

Bernice Simone Elger

Institute for Biomedical Ethics, University of Basel Basel Switzerland

D

Dorota Gabrys

Department of Radiation Oncology Maria Sklodowska‐Curie National Research Institute of Oncology‐Gliwice Branch Glliwice Poland

P

Peter Hoskin

Mount Vernon Cancer Center and University of Manchester Manchester UK

M

Maximilian Niyazi

Department of Radiation Oncology University Hospital Tubingen Tubingen Germany

D

David Pasquier

Academic Department of Radiation Oncology Oscar Lambret Center Lille France

K

Kelly Paradis

Department of Radiation Oncology Michigan Medicine Ann Arbor Michigan USA

O

Orit Kaidar‐Person

Oncology Institute Sheba Medical Center Ramat Gan Israel

C

Corien Plaisier

Reintegration Coach Breda Netherlands

N

Nicole C. Schmitt

Department of Otolaryngology‐Head and Neck Surgery Emory University School of Medicine Atlanta Georgia USA

C

Conor E. Steuer

Department of Hematology and Medical Oncology Emory University Atlanta Georgia USA

J

Juliette Thariat

Department of Radiation Oncology Baclesse Cancer Center Caen France

S

Sue S. Yom

Department of Radiation Oncology University of California‐San Francisco San Francisco California USA

P

Philip Poortmans

Department of Radiation Oncology Iridium Netwerk Wilrijk‐Antwerp Belgium

E

Eliana Vasquez Osorio

Division of Cancer Sciences University of Manchester Manchester UK

N

Nicolaus Andratschke

Department of Radiation Oncology University Hospital Zurich University of Zurich Zurich Switzerland